Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County

Journal of Substance Abuse Treatment

Volumn 63, Issue , 2016, Pages 66-71

  Cousins, Sarah J ^a   Radfar, Seyed Ramin ^a,b   Crèvecoeur MacPhail, Desirée ^a   Ang, Alfonso ^a   Darfler, Kendall ^a   Rawson, Richard A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Extended release naltrexone; Heroin; Medication assisted treatment; Opioid use disorder; Opioids

Indexed keywords

DIAMORPHINE; EXTENDED RELEASE NALTREXONE; NALTREXONE; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; NARCOTIC ANTAGONIST;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DEPENDENCE TREATMENT; DRUG USE; DRUG UTILIZATION; FEMALE; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENTAL DISEASE; OPIATE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; UNITED STATES; WITHDRAWAL SYNDROME; CALIFORNIA; COMPARATIVE STUDY; CRAVING; DELAYED RELEASE FORMULATION; MIDDLE AGED; OPIOID-RELATED DISORDERS; PHYSIOLOGY; SUBSTANCE ABUSE;

ADULT; CRAVING; DELAYED-ACTION PREPARATIONS; FEMALE; HEROIN DEPENDENCE; HUMANS; LOS ANGELES; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84959116663     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2015.12.004     Document Type: Article

References (29)

1. Banta-Green C.J., Maynard C., Koepsell T.D., Wells E.A., Donovan D.M. Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users. Addiction 2009, 104:775-783.
2. Bouchery E.E., Harwood H.J., Sacks J.J., Simon C.J., Brewer R.D. Economic costs of excessive alcohol consumption in the U.S., 2006. American Journal of Preventive Medicine 2011, 41:516-524.
3. Bryson W.C., McConnell J., Korthuis P.T., McCarty D. Extended-release naltrexone for alcohol dependence: Persistence and healthcare costs and utilization. American Journal of Managed Care 2011, 17(Suppl. 8):S222-S234.
4. Capone T., Brahen L., Condren R., Kordal N., Melchiondam R., Peterson M. Retention and outcome in a narcotic antagonist treatment program. Journal of Clinical Psychology 1986, 42:825-833.
5. Center for Substance Abuse Treatment (CSAT) Medication-assisted treatment for opioid addiction in opioid treatment programs 2005, Author, Rockville, MD.
6. Chakrabarti A., Woody G.E., Griffin M.L., Subramaniam G., Weiss R.D. Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: Secondary analyses from a NIDA Clinical Trials Network study. Drug and Alcohol Dependence 2010, 107:253-256.
7. Comer S.D., Sullivan M.A., Yu E., Rothenberg J.L., Kleber H.D., Kampman K., O'Brien C.P. Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Archives of General Psychiatry 2006, 63:210-218.
8. Cousins S.J., Denering L., Crèvecoeur-MacPhail D., Viernes J., Sugita W., Barger J., Rawson R.A. A demonstration project Implementing extended-release naltrexone in Los Angeles County. Substance Abuse 2015, (Epub ahead of print).
9. Coviello D.M., Cornish J.W., Lynch K.G., Alterman A.I., O'Brien C.P. A randomized trial of oral naltrexone for treating opioid-dependent offenders. American Journal on Addictions 2010, 19:422-432.
10. Coviello D.M., Cornish J.W., Lynch K.G., Boney T.Y., Clark C.A., Lee J.D., O'Brien C.P. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Substance Abuse 2012, 33:48-59.
11. Crèvecoeur D., Rutkowski B., Rawson R.A. The rise in treatment admissions for primary methamphetamine use in Los Angeles County from 2001 through 2005. Journal of Psychoactive Drugs 2007, (SARC Suppl. 4):383-392.
12. Crits-Christoph P., Lundy C., Stringer M., Gallop R., Gastfriend D.R. Extended-release naltrexone for alcohol and opioid problems in Missouri parolees and probationers. Journal of Substance Abuse Treatment 2015, 56:54-60.
13. DeFulio A., Everly J.J., Leoutsakos J.M., Umbricht A., Fingerhood M., Bigelow G.E., Silverman K. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: A randomized controlled trial. Drug and Alcohol Dependence 2012, 120:48-54.
14. Dreifuss J.A., Griffin M.L., Frost K., Fitzmaurice G.M., Potter J.S., Fiellin D.A., Weiss R.D. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug and Alcohol Dependence 2013, 131:112-118.
15. Fischer B., Cruz M.F., Patra J., Rehm J. Predictors of methadone maintenance treatment utilization in a multisite cohort of illicit opioid users (OPICAN). Journal of Substance Abuse Treatment 2008, 34:340-346.
16. Fishman M.J., Winstanley E.L., Curran E., Garrett S., Subramaniam G. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: Preliminary case-series and feasibility. Addiction 2010, 105:1669-1676.
17. Flannery B., Volpicelli J., Pettinatti H. Psychometric properties of the Penn Alcohol Craving Scale. Alcoholism: Clinical and Experimental Research 1999, 23:1289-1295.
18. Greenstein R.A., Evans B.D., McLellan A.T., O'Brien C.P. Predictors of favorable outcome following naltrexone treatment. Drug and Alcohol Dependence 1983, 12:173-180.
19. Kleber H.D. Pharmacologic treatments for opioid dependence: Detoxification and maintenance options. Dialogues in Clinical Neuroscience 2007, 9:455-470.
20. Krupitsky E., Nunes E.V., Ling W., Gastfriend D.R., Memisoglu A., Silverman B.L. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: Long-term safety and effectiveness. Addiction 2013, 108:1628-1637.
21. Krupitsky E., Nunes E.V., Ling W., Illeperuma A., Gastfriend D.R., Silverman B.L. Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011, 377:1506-1513.
22. Krupitsky E., Zvartau E., Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Current Psychiatry Reports 2010, 12:448-453.
23. Lee J.D., McDonald R., Grossman E., McNeely J., Laska E., Rotrosen J., Gourevitch M.N. Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial. Addiction 2015, 110:1008-1014.
24. McCabe B.E., Santisteban D.A., Mena M.P., Duchene D.M., McLean C., Monroe M. Engagement, retention, and abstinence for three types of opioid users in Florida. Substance Use & Misuse 2013, 48:623-634.
25. Moore B.A., Fiellin D.A., Barry D.T., Sullivan L.E., Chawarski M.C., O'Connor P.G., Schottenfeld R.S. Primary care office-based buprenorphine treatment: Comparison of heroin and prescription opioid dependent patients. Journal of General Internal Medicine 2007, 22:527-530.
26. Nunes E.V., Krupitsky E., Ling W., Zummo J., Memisoglu A., Silverman B.L., Gastfriend D.R. Treating opioid dependence with injectable extended-release naltrexone (XR-NTX): Who will respond?. Journal of Addiction Medicine 2015, 9:238-243.
27. Rubio G., Ponce G., Rodriguez-Jimenez R., Jimenez-Arriero M.A., Hoenicka J., Palomo T. Clinical predictors of response to naltrexone in alcoholic patients: Who benefits most from treatment with naltrexone?. Alcohol and Alcoholism 2005, 40:227-233.
28. Sullivan M.A., Bisaga A., Mariani J.J., Glass A., Levin F.R., Comer S.D., Nunes E.V. Naltrexone treatment for opioid dependence: Does its effectiveness depend on testing the blockade?. Drug and Alcohol Dependence 2013, 133:80-85.
29. Sullivan M.A., Rothenberg J.L., Vosburg S.K., Church S.H., Feldman S.J., Epstein E.M., Nunes E.V. Predictors of retention in naltrexone maintenance for opioid dependence: Analysis of a stage I trial. American Journal on Addictions 2006, 15:150-159.